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Introduction subcutaneous IFN (Interferon Alpha-n1 Wellferon) in
accordance with the MRC CML 4 trial protocol.
Interferon (IFN) has an established place in the treat- Following 12 weeks of IFN therapy she presented
with severe digital ischaemia of both hands andment of chronic myeloid leukaemia (CML) achieving
a haematological response in 60–80% of patients and distressing throbbing pain necessitating 400 mg mor-
phine sulphate daily. The tips of the digits were non-significantly longer survival than that following con-
ventional chemotherapy alone.1 Adverse effects, often viable, ulcerated and infected (Fig. 1A). Upper limb
pulses were all palpable. Autoimmune (includingdose dependent, include a self-limiting flu-like illness,
thyroid dysfunction, lupus-like syndrome and Ray- anti-ds DNA, cryoglobulins), coagulation and throm-
bophilia screens were all negative or within normalnaud’s phenomenon.
A patient with CML who sustained severe digital range. Subclavian angiography revealed uneven ob-
struction of the digital arteries (Fig. 1B).ischaemia of both hands attributable to IFN therapy
and who benefited from ketanserin therapy is reported. Intravenous ketanserin was commenced and 48 h
later dextran 40, enoxaparin and aspirin added;
cephaclor was started to counter infection and hy-
droxyurea continued. Within 3 weeks of intravenous
Case Summary ketanserin therapy, flow to the digits assessed by
Doppler had reverted to normal, the fingers began toA 27-year-old female with no cardiovascular risk fac- heal, and her analgesic requirements decreased. Ators was referred with advanced digital ischaemia of month later debridement resulted in excellent pre-both hands. She originally presented with a profound servation of the finger tips. She underwent successfulnormocytic normochromic anaemia (Hb 6.2 g/dl), bone marrow transplantation and remained on oralmarked thrombocytosis (platelets 2273×109/l) with ketanserin 40 mg bd for 6 months after discharge.platelet anisocytosis, giant platelets and occasional
blasts. Bone marrow aspiration, trephine biopsy and
bone marrow cyogenetics confirmed Philadelphia
chromosome positive CML (BCR/ABL fusion gene Discussion
detected by RT PCR). Treatment with hydroxyurea was
initiated to control the platelet count and subsequently Raynaud’s phenomenon, a known side effect of IFN
therapy,2 represents either an exacerbation of pre-
existing autoimmune disease or a direct unknown
∗ Please address all correspondence to: A. Sachithanandan, Division vasospastic effect. Arteriographically documented dig-of Vascular Surgery, Wards 17/18, Royal Victoria Hospital, Belfast
BT12 6BA. ital artery occlusions causing finger tip necrosis are
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Fig. 1. (A) Pre-treatment photograph demonstrating Interferon induced severe digital ischaemia. (B) Palmar arch arteriogram illustrating
uneven obstruction of digital arteries.
a new and rare finding2. Necrotising vasculitic skin formation of platelet aggregates and induce vaso-
constriction.4 The platelet plug and damaged endo-reactions occurring in CML patients on IFN are in-
dependent of IFN type, administration modality, dur- thelium release vasoactive substances which trigger
the clotting cascade causing microcirculatory throm-ation of therapy, stage of disease and cytogenetic
response to treatment.3 bosis and ischaemia of peripheral tissues.
Neither CML nor the drugs administered are knownPlatelet activation following vascular injury results
in release of endogenous agonists such as serotonin, to induce vasospastic disorders5 and the platelet count
in this patient remained normal. Hence it would beADP and thromboxane A2 which accelerate the
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reasonable to conclude that digital artery occlusion reversing the ischaemia and preserving the viability
of the digits was clearly observed in this case.is a rare side effect of IFN therapy, and in such
circumstances should be stopped.
Serotonin modulates the contractile activity of vas-
Referencescular smooth muscle cells (VSMC) and activation of
serotonergic 5-HT2 receptors causes vasoconstriction. 1 Italian Cooperative Study Group on CML. Interferon 2A as
compared with conventional chemotherapy for the treatment ofSerotonin also activates platelets and in vitro induces
CML. N Engl J Med 1994; 330: 820–825.shape change and weak reversible platelet aggrega-
2 Creutzig A, Freund M. Severe Raynaud’s syndrome associated
tion.4 with interferon therapy. Angiology 1996; 47: 185–187.
3 Krainick U, Kantarjian H, Broussard S, Talpaz M. LocalKetanserin is a selective antagonist of the 5-HT2
cutaneous necrotizing lesions associated with interferon injections.serotonin receptor devoid of partial agonist properties J Interferon & Cytokine Res 1988; 18: 823–827.
and has moderate alpha-1 adrenergic receptor blocking 4 Qi R, Ozaki Y, Setoh K et al. Quantitative measurement of various
5-Hydroxytryptamine receptor antagonists on platelet activationeffects.4 It inhibits serotonin induced platelet ag-
induced by serotonin. Thrombosis Research 1996; 81: 43–54.gregation and also prevents vasoconstriction in a dose- 5 Doll DC, Yarbro JW. Vascular toxicity associated with anti-
neoplastic agents. Semin Oncol 1992; 19: 580–596.dependent manner.3,4 The efficacy of ketanserin in
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